knowledge -WSS

knowledge

author：Wikipedia 2025-08-26 10:54:50 - browse：3

WASHINGTON — Grail is aggressively lobbying to get Medicare to pay for its cancer-screening test Galleri — but experts tell STAT that the company has a far more complicated path to that end than the makers of most medicines or medical devices.

Grail’s controversial blood test Galleri screens for multiple cancers. The Food and Drug Administration has not yet approved it, so Medicare hasn’t had to make a decision on whether to cover it or not. Right now, most people pay for it out of pocket. It runs about $950.

In general, Medicare covers FDA-approved medicines and medical devices that help diagnose or treat disease or injury. But there’s a catch for Grail: Medicare doesn’t cover tests that simply screen healthy people, as Galleri does.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Guidelines to prevent youth baseball injuries need more muscle
Next article： Akili, maker of video game for ADHD, to be acquired for 34 million

WSS

Startling documents reveal new facets of Sacklers' opioid empire

Latest bird flu infection made farmworker sicker than earlier cases

Report: NIH

Childbirth

Startling documents reveal new facets of Sacklers' opioid empire

Insmed lung disease drug hits target in key Phase 3 trial

hotspot

knowledge

leisure time

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Adam's Biotech Scorecard: Do Sarepta's exon

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Childbirth

Heart attack and stroke risk calculators need revising

Dark money group runs ads on China biotech bill

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Readout Newsletter: Insmed, Asahi Kasei, Agios, Royalty Pharma

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Average age of first period drops to 11.9 years, study shows

hotspot

David Sabatini, ex

Insmed lung disease drug hits target in key Phase 3 trial

Gene therapies for deafness raise the question: Do deaf people want a 'cure'?

Report: NIH

Report: NIH

Focused ultrasound for uterine fibroids: an uphill battle

leisure time

leisure time

focus

hotspot